Trial Profile

The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MEDI 3250 (Primary) ; GSK 2321138A
Indications Influenza virus infections
Focus Therapeutic Use
Acronyms LAIV/EHPC

Most Recent Events

04 Sep 2017 Status changed from active, no longer recruiting to completed.
01 May 2017 Status changed from recruiting to active, no longer recruiting.
12 Dec 2015 Accrual to date is 47% according to United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com